FINANCIAL SUPERVISION AUTHORITY

Current report No. 6/2019
Date prepared: 2019-04-01
Abbreviated name of the issuer: MABION S.A.
Subject: Information on the registration procedure for MabionCD20 in Turkey
Legal basis: Article 17 paragraph 1 MAR - confidential information.

Contents of the report:

The Management Board of Mabion S.A. ("Company") informs that it received a letter from the Health Ministry of Turkey on the April 1, 2019 regarding the issue of meeting the requirements of Good Manufacturing Practice (GMP) recognized in the territory of Turkey by the Scientific and Industrial Complex of Medical Biotechnology ("Complex") in Konstantynow Lodzki.

The letter was published as a result of inspection, that had been conducted in February this year in the Complex. In accordance with received letter, no critical deficiency had been detected, while conducting the inspection. The remaining recognized deficiencies are few and in the Company's opinion easy to correct, therefore the Company assesses positively the completed inspection and the nature of given comments.

The Company remains in contact with the Turkish Agency for the further processing in order to submit documentation of registration for MabionCD20 in the territory of Turkey. The Company will not report any further interactions with the Turkish Agency until the submission of the registration dossier due to the small significance of these events.

This information is considered as significant by the Company, as the positive verification of the GMP system in relation to Turkish requirements is a necessary event to submit a dossier in this country and today's event is the first milestone in this respect. Turkey has its own independent regulatory system, which is why European certification does not give GMP status in Turkey.